About Post-Menopausal Vaginal Atrophy Drugs
Vaginal atrophy also known as atrophic vaginitis is defined as a decrease in the production of estrogen after menopause, leading to thinning, drying, and reduced elasticity of the vaginal tissues. Up to 40% of post-menopausal women have symptoms of atrophic vaginitis. It typically affects women in the age group of 45-55 years. PVA result in symptoms such as itching, burning, dryness, and dyspareunia. Topical preparations such as hormone replacement therapy (HRT) and estrogen creams are used to treat PVA.
Technavio’s analysts forecast the global PVA drugs market to grow at a CAGR of 7.13% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global PVA drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of drugs (creams, tablets, patches, and rings) used to treat PVA.
The market is divided into the following segments based on geography:
• Americas
• EMEA
• APAC
Technavio's report, Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Pfizer Inc.
• Allergan Inc.
• Shionogi & Co. Ltd.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
Other prominent vendors
• Bayer
• Bionovo
• EndoCeutics
• Foamix Pharmaceuticals
• Ligand Pharmaceuticals
• Pantarhei Bioscience
• Pep-Tonic Medical
• TherapeuticsMD
• Upsher-Smith Laboratories
Market driver
• Favorable healthcare reforms in the US
• For a full, detailed list, view our report
Market challenge
• Patent expiry of branded products
• For a full, detailed list, view our report
Market trend
• Paradigm shift to non-estrogenic therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Key buying criteria
PART 05: Overview: Vaginal atrophy
• Symptoms
• Causes
• Pathophysiology
• Diagnosis
• Treatment
• Epidemiology
PART 06: Branded drug profiles
• Activella
• Enjuvia
• Estrace
• Femring
• Premarin
• Osphena
• Vagifem
PART 07: Market landscape
• Market overview
• Market size and forecast
PART 08: Market segmentation by drug class
• Topical estrogen
• Systemic estrogen
PART 09: Geographical segmentation
• Global PVA drugs market by geographical segmentation 2015-2020
• PVA drugs market in Americas
• PVA drugs market in US
• PVA drugs market in EMEA
• PVA drugs market in Europe
• PVA drugs market in APAC
• PVA drugs market in Japan
PART 10: Market drivers
• Significant unmet medical needs
• Favorable healthcare reforms in US
• Increase in awareness of PVA
• Cost-effective OTC drugs
PART 11: Impact of drivers
PART 12: Market challenges
• Patent expiry of branded products
• Low diagnosis rates
• Poor patient adherence
• Side effects of drugs
PART 13: Impact of drivers and challenges
PART 14: Market trends
• Paradigm shift to non-estrogenic therapies
• Increased R&D
• Patient assistance programs
• Strategic alliances
PART 15: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Pfizer
• Allergan
• Shionogi
• Novo Nordisk
• Teva Pharmaceutical
• Other prominent vendors
PART 16: Appendix
• List of abbreviations
PART 17: Explore Technavio
?
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for PVA drugs
Exhibit 03: Symptoms of PVA
Exhibit 04:
Exhibit 05: Percentage of major vaginal atrophy symptoms in postmenopausal women
Exhibit 06: Causes of PVA
Exhibit 07: Effects of estrogen deficiency
Exhibit 08: Treatment for PVA
Exhibit 09: Some hormonal treatments for PVA
Exhibit 10: Top concerns associated with OTC lubricants or moisturizers for PVA
Exhibit 11: Top concerns about use of vaginal estrogen for PVA
Exhibit 12: Prevalence of vaginal atrophy symptoms in postmenopausal women by country 2014
Exhibit 13: Global PVA drugs market 2015-2020 ($ billions)
Exhibit 14: Five forces analysis
Exhibit 15: Global PVA drugs market segmentation by drug class
Exhibit 16: Global PVA drugs market share by drug class
Exhibit 17: Preference for oral or vaginal ROA by age 2014
Exhibit 18: Global PVA drugs market by geography 2015
Exhibit 19: Global PVA drugs market revenue by geography 2015-2020 ($ millions)
Exhibit 20: Global PVA drugs market: YoY revenue and growth based on geography 2015-2020 ($ millions)
Exhibit 21: PVA drugs market in Americas 2015-2020 ($ billions)
Exhibit 22: PVA drugs market in Americas by country 2015
Exhibit 23: PVA drugs market in US 2015-2020 ($ billions)
Exhibit 24: Share of PVA drugs in US by drug class 2015
Exhibit 25: PVA drugs market in EMEA 2015-2020 ($ millions)
Exhibit 26: PVA drugs market in EMEA by region 2015
Exhibit 27: PVA drugs market in Europe 2015-2020 ($ millions)
Exhibit 28: Share of PVA drugs in Europe by drug class 2015
Exhibit 29: PVA drugs market in APAC 2015-2020 ($ millions)
Exhibit 30: PVA drugs market in APAC by country 2015
Exhibit 31: PVA drugs market in Japan 2015-2020 ($ millions)
Exhibit 32: Share of PVA drugs in Japan by drug class 2015
Exhibit 33: Specific OTC treatments for vaginal atrophy
Exhibit 34: Impact of drivers
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Global PVA drugs market share analysis 2015
Exhibit 37: Market share analysis of top vendors 2015
Exhibit 38: Timeline and history of Premarin
Exhibit 39: Pfizer: YoY revenue and growth rate of Premarin 2013-2015 ($ billions)
Exhibit 40: Pfizer: Geographical segmentation of Premarin 2015
Exhibit 41: Pfizer: Key takeaways
Exhibit 42: Allergan: YoY revenue and growth rate of Estrace 2013-2015 ($ millions)
Exhibit 43: Allergan: Key takeaways
Exhibit 44: YoY revenue comparison of Osphena 2013 and 2014 ($ millions)
Exhibit 45: Shionogi: Key takeaways
Exhibit 46: Novo Nordisk: Key takeaways
Exhibit 47: Timeline for Enjuvia
Exhibit 48: Teva Pharmaceutical: Key takeaways
